Vertiv Holdings Co <VRT.N>: BofA Global Research cuts price objective to $375 from $440
VRT•Related News
U.S. June personal income data
SPY•
Newly FDA-Approved Revtorpyk™ (Gedatolisib) Included In The National Comprehensive Cancer Network® (Nccn®) Clinical Practice Guidelines For Hr+/Her2- Locally Advanced Or Metastatic Breast Cancer
CELC•
Nixxy Announces Strategic AI Infrastructure Platform Initiative
NIXX•
Red River Bancshares Q2 net interest margin rises, expects higher loan growth in H2
RRBI•
Prog Holdings Inc <PRG.N>: B. Riley raises target price to $64 from $57
PRG•